Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

PTC Therapeutics announced Monday that its splicing drug for Huntington’s disease met the primary endpoint of a Phase 2 study ...

Bristol Myers Squibb is letting go of 516 workers in New Jersey as part of a wide-reaching cost-cutting plan aimed at making ...

Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new ...

Initial clinical data from Genocury and EsoBiotec shows promise for in vivo CAR-T therapy, with complete remission in ...

Topas Therapeutics reveals first data from celiac disease therapy study, showing promise in immune system retraining with ...

Not many would argue that Biotech is one of the riskiest industries on the globe. With costs hovering in the hundreds of millions of dollars, competitors ...

Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, or AAVs — the vi­ral vec­tors com­mon­ly used to ...

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC.